PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2009 November; 53(11): 4718–4725.
Published online 2009 August 17. doi:  10.1128/AAC.00802-09
PMCID: PMC2772353

Impact of Spore Biology on the Rate of Kill and Suppression of Resistance in Bacillus anthracis[down-pointing small open triangle]

Abstract

Bacillus anthracis is complex because of its spore form. The spore is invulnerable to antibiotic action. It also has an impact on the emergence of resistance. We employed the hollow-fiber infection model to study the impacts of different doses and schedules of moxifloxacin on the total-organism population, the spore population, and the subpopulations of vegetative- and spore-phase organisms that were resistant to moxifloxacin. We then generated a mathematical model of the impact of moxifloxacin, administered by continuous infusion or once daily, on vegetative- and spore-phase organisms. The ratio of the rate constant for vegetative-phase cells going to spore phase (Kvs) to the rate constant for spore-phase cells going to vegetative phase (Ksv) determines the rate of organism clearance. The continuous-infusion drug profile is more easily sensed as a threat; the Kvs/Ksv ratio increases at lower drug exposures (possibly related to quorum sensing). This movement to spore phase protects the organism but makes the emergence of resistance less likely. Suppression of resistance requires a higher level of drug exposure with once-daily administration than with a continuous infusion, a difference that is related to vegetative-to-spore (and back) transitioning. Spore biology has a major impact on drug therapy and resistance suppression. These findings explain why all drugs of different classes have approximately the same rate of organism clearance for Bacillus anthracis.

Bacillus anthracis remains a major threat for intentional release and would be expected to cause considerable mortality and morbidity. Both ciprofloxacin and levofloxacin have gained FDA approval for the postexposure prophylaxis of anthrax infections. Moxifloxacin is also a fluoroquinolone (9), but with greater potency for gram-positive pathogens. This makes it an appealing choice for evaluation.

Fluoroquinolones are also highly active against other bioterror pathogens, such as Yersinia pestis (6, 7). Bacillus anthracis remains a special case because it forms spores. This protects this pathogen from rapid death due to drug therapy as well as from other environmental challenges. We have studied the Δ-Sterne strain and its isogenic mutant (CR4) that lacks the ability to form spores. In our original levofloxacin evaluation, the non-spore-forming mutant was eradicated from the system very quickly (3). We have seen this repeatedly for drugs of different classes (data not shown). The spore form provides a ready refuge from the onslaught of chemotherapy.

In this investigation, we wished to evaluate moxifloxacin against Bacillus anthracis. Since we have previously demonstrated that the schedule of administration has an impact on the likelihood of the emergence of resistance to linezolid (8), we wished to examine the impact of once-daily administration of moxifloxacin versus continuous-infusion administration. Finally, we recognized how complex the spore form makes this model system. Consequently, we wished to model multiple system outputs simultaneously, and we generated a mathematical model examining the total population (sensitive plus resistant organisms, both vegetative and spore phase), the total spore population as determined after heat shock (antibiotic-sensitive plus antibiotic-resistant spore-phase organisms), the total antibiotic-resistant population (vegetative plus spore phase), and the resistant population after heat shock (which measures antibiotic-resistant spores). We also measured moxifloxacin concentrations to determine how they had an impact (or not) on each of the populations measured.

MATERIALS AND METHODS

Bacteria, media, susceptibility testing, and frequency of mutation to resistance.

The Δ-Sterne strain of Bacillus anthracis was evaluated. This strain lacks the pX01 and pX02 virulence plasmids containing the toxin and capsule genes, respectively. Moxifloxacin powder was kindly supplied by Bayer Pharmaceuticals (Wuppertal, Germany).

MICs of moxifloxacin were determined simultaneously by the macrobroth and agar dilution methods in Mueller-Hinton II broth (MHB) and Mueller-Hinton II agar (MHA) using the methods outlined by the CLSI (2). MICs were read after 24 h of incubation at 35°C. Trailing endpoints were observed. After discussion with H. Heine, our coinvestigator at USAMRIID and a member of the CLSI advisory committee, the MIC was defined as the lowest moxifloxacin dilution that resulted in a ≥80% reduction in growth compared to the growth controls. Minimal bactericidal concentrations (MBCs) were determined using standard methods (1). The frequencies of mutation to resistance in the presence of moxifloxacin concentrations equivalent to 2.5 times the MIC (2.5× MIC) were determined in three trials.

In vitro HF pharmacodynamic infection model.

The hollow-fiber (HF) infection model described previously (3, 7, 8) was used to study the responses of B. anthracis to moxifloxacin exposures, simulating human pharmacokinetics. HF cartridges (FiberCell Systems, Frederick, MD) consist of bundles of HF capillaries encased in a plastic housing. The fibers have numerous pores that permit the passage of nutrients and low-molecular-weight species, such as antibiotics, but exclude bacteria. Approximately 15 ml of extracapillary space lies between the fibers and the cartridge housing. The medium within the central reservoir was continuously pumped through the HFs, and low-molecular weight compounds rapidly equilibrated across the fibers with the extracapillary space. Thus, microorganisms that were inoculated into the extracapillary space were exposed to conditions approximating those that prevailed in the central reservoir.

Antibiotic was infused over 1 h into the central reservoir at predetermined time points by syringe pumps. Antibiotic-containing medium was isovolumetrically replaced with drug-free medium, simulating a half-life of 12 h. The rate constant of elimination of antibiotic was the rate of fresh medium infusion divided by the volume of the medium in the total system. The system simulated a single-compartment model with exponential elimination. The drug was also administered by continuous infusion.

For each experiment, 15 ml of a B. anthracis suspension (107 CFU/ml) was inoculated into the extracapillary space of multiple HF cartridges, and the experiment was initiated by infusing antibiotic. At predetermined time points, an 800-μl sample of bacteria was collected from each HF system. Samples were centrifuged twice, resuspended, and quantitatively cultured onto drug-free MHA (for total spore plus vegetative organisms) and onto MHA containing moxifloxacin at 2.5× MIC (for resistant spore and vegetative organisms). The media taken from the central reservoir over the first 48 h were assayed for moxifloxacin concentrations to confirm that the desired pharmacokinetic profiles were achieved. The drug concentrations measured were within 10% of the targeted values as measured by the area under the concentration-time curve from 0 to 24 h (AUC0-24) (data not shown). The experiment was duplicated.

Determination of moxifloxacin concentrations.

Samples obtained from each treatment arm were stored at −80°C until they were assayed for their moxifloxacin concentrations.

Moxifloxacin concentrations in MHB were determined by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS; Applied Biosystems/MDS Sciex API 5000 system). To MHB samples (0.05 ml), acetonitrile (0.1 ml) was added. After mixing, samples were centrifuged for 5 min at 3,600 rpm. The supernatant was diluted with buffer. Fifteen microliters of each sample was chromatographed on a reversed-phase column (Phenomenex Aqua C18 column; 50 by 4.6 mm), eluted with an isocratic solvent system (1 mM ammonium formate buffer and acetonitrile [30:70, vol/vol]), and monitored by LC-MS-MS with a multiple reaction monitoring method: precursor → product ion for moxifloxacin m/z 402 → m/z 358 (in positive mode). Under these conditions, moxifloxacin was eluted after approximately 1 min. Analyst software (version 1.4.1, 1999 to 2004; Applied Biosystems/MDS Sciex, Toronto, Canada) was used for the evaluation of chromatograms.

The assay was linear over a range of 0.047 to 5.04 μg/ml (r2 > 0.99). The interday coefficients of variation from quality control samples at five levels (0.049, 0.12, 0.49, 3.74, and 5.00 μg/ml) in replicates of at least three on each analysis day ranged from 3.0 to 5.7%, with recoveries ranging from 96.6 to 109%.

HF system experimental design.

The moxifloxacin dose range experiments consisted of a no-treatment control arm and a total of nine other systems. In five systems, regimens for 50 mg through 250 mg of moxifloxacin given once daily in 50-mg increments were simulated. In four other systems, continuous-infusion regimens producing the same AUC0-24 as administration by the once-daily administration regimens were studied (exposures equivalent to doses of 100 mg, 150 mg, 200 mg, and 250 mg). All drug regimens simulated the moxifloxacin free-drug concentrations. Samples were taken from each HF system over the 14-day experiment. Over the course of the study, bacterial samples collected from each HF system were divided into two aliquots. The first aliquot was washed twice to prevent drug carryover before it was quantitatively plated onto drug-free MHA and onto MHA containing 2.5× MIC of moxifloxacin for enumeration of the total (spore plus vegetative) B. anthracis population and of the spore-plus-vegetative B. anthracis subpopulation that was resistant to >2.5× baseline MIC, respectively. The second aliquot of the bacterial suspension was heat shocked at 65°C for 30 min in order to kill the vegetative-phase organisms. After heat shock, the aliquot was washed to prevent drug carryover and was then quantitatively cultured on antibiotic-free and moxifloxacin-supplemented agar plates in order to characterize the effect of each moxifloxacin regimen on the total spore population and the spore population that was resistant to >2.5× MIC of moxifloxacin.

Mathematical modeling of drug exposure-response relationships of the total bacterial population and the resistant bacterial subpopulation for both vegetative-phase organisms and spore forms.

In order to understand mathematically the spore- plus vegetative-phase organism system with susceptible and resistant populations for each, five simultaneous parallel inhomogeneous differential equations (seven equations overall), shown below, were used to describe the time course of moxifloxacin concentrations and the total populations and resistant subpopulations for all counts and for spore counts only.

The different drug treatment regimens were simultaneously comodeled in a population sense using the BigNPAG population modeling program (6). Bayesian estimates were generated for each regimen.

equation M1
(1)

where X1 is the moxifloxacin amount in the central compartment, R1 is the piecewise constant infusion rate of drug, CL is the moxifloxacin clearance, and V is the virtual volume of the central compartment.

equation M2
(2)

equation M3
(3)

equation M4
(4)

equation M5
(5)

where X2 and X3 are the total counts (vegetative plus spore phases) of Bacillus anthracis for the sensitive and resistant populations, respectively; Kg-s and Kg-r are the first-order growth rate constants for the sensitive and resistant populations, respectively; POPMAX is the maximal population of total counts; Kk-s and Kk-r are the first-order kill rate constants for the sensitive and resistant populations; Ms and Mr are the sigmoid Emax kill functions for the sensitive and resistant populations, wherein Hs and Hr are the Hill constants for the sensitive and resistant populations; and C50-s and C50-r are the moxifloxacin concentrations at which the kill rate is half-maximal for the sensitive and resistant populations.

equation M6
(6)

equation M7
(7)

where X4 and X5 are the populations of drug-sensitive and drug-resistant spores present after heat shock, respectively, and Kvs and Ksv are the first-order rate constants of vegetative-phase cells going to spore phase and spore-phase cells going to vegetative phase, respectively.

System outputs.

System output 1, calculated as X(1)/P(1), where P(1) is the volume of the control compartment, is the moxifloxacin drug concentration. System output 2, calculated as log10 [X(2) + X(3)], is the total population of all cells (vegetative plus spore phase, sensitive plus resistant) placed on drug-free plates. System output 3, calculated as log10 X(3), is the total population of resistant cells (vegetative plus spore phase), where subculture volumes are grown on moxifloxacin-containing plates. System output 4, calculated as log10 [X(4) + X(5)], is the total counts after heat shock with culture on drug-free plates. System output 5, calculated as log10 X(5), is the counts after heat shock with culture on moxifloxacin-containing plates.

RESULTS

MIC/MBC of moxifloxacin for B. anthracis strain Δ-Sterne.

The modal MIC of moxifloxacin for the Δ-Sterne strain was 0.06 mg/liter, and the modal MBC for this strain was 1.0 mg/liter (performed in duplicate on three occasions).

Total population and total spore colony counts for the Δ-Sterne strain of B. anthracis.

The total (vegetative plus spore phase, sensitive plus resistant) counts of Bacillus anthracis grown in HF units exposed to a continuous infusion of moxifloxacin (free AUC0-24 exposures equivalent to doses of 100 mg, 150 mg, 200 mg, and 250 mg per day) plus a no-treatment control are displayed in Fig. Fig.1A;1A; those for once-daily administration (50 mg, 100 mg, 150 mg, 200 mg, and 250 mg per day) are displayed in Fig. Fig.2A.2A. The corresponding data for spores (post-heat shock) are displayed in Fig. Fig.1B1B and and2B.2B. All regimens producing exposures equivalent to ≤100 mg of moxifloxacin failed (allowed the emergence of resistance). Of note, the continuous-infusion regimen equivalent to 100 mg of moxifloxacin failed later (day 8 versus day 3) than the once-daily regimen. All regimens of 200- or 250 mg-equivalent exposures succeeded (resistance amplification was suppressed). At the equivalent of 150 mg, the continuous regimen succeeded while the once-daily regimen failed between days 3 and 4.

FIG. 1.
Impact of a no-treatment control and of moxifloxacin administered at different continuous-infusion exposures on total colony counts (A), spore colony counts (after heat shock) (B), moxifloxacin-resistant colony counts (C), and moxifloxacin-resistant spore ...
FIG. 2.
Impact of a no-treatment control and of moxifloxacin administered at different daily administration exposures on total colony counts (A), spore colony counts (after heat shock) (B), moxifloxacin-resistant colony counts (C), and moxifloxacin-resistant ...

Moxifloxacin-resistant organisms.

The total moxifloxacin-resistant spore and vegetative-organism counts and the counts after heat shock (moxifloxacin-resistant spore counts) for continuous regimens and once-daily regimens are displayed in Fig. 1C and D and Fig. 2C and D, respectively. For the failed regimens in both administration groups, the emergence of resistance accounts for the upturn in total colony counts (Fig. (Fig.1A1A and and2A).2A). Interestingly, in the once-daily administration group, the resistant organisms are able to invade the spore population and amplify, at least in the 50-, 100-, and 150-mg-equivalent groups. Also of importance, for regimens where both once-daily and continuous-infusion administration failed, the once-daily administration group failed earlier.

Fit of the model to the data.

The model described in Materials and Methods was fit to the data. The mean and median point estimates of the parameters and their standard deviations are shown in Table Table1.1. The overall fit of the model to the data after the Bayesian step was quite acceptable for all five outputs (drug concentrations, total population, total resistant population, spore population, and resistant spore population) and is shown in Table Table2.2. Bayesian estimates for the model parameters are provided for the reader in Table Table33 (for continuous infusion) and Table Table44 (for daily administration).

TABLE 1.
Parameter values for the two modes of administration of moxifloxacin
TABLE 2.
Fit of the model to the data for all system outputs after the Bayesian step
TABLE 3.
Bayesian parameter values for moxifloxacin administered as a continuous infusion
TABLE 4.
Bayesian parameter values for moxifloxacin administered once daily

Importance of the spore pathway.

Examination of the rate constants for the vegetative-phase-to-spore transition (Kvs) and back (Ksv) demonstrates that there is a difference in the Bayesian point estimates as a function of drug exposure between the daily-administration group and the continuous-infusion group. Examination of Fig. 3A and B demonstrates that the Kvs/Ksv ratio transitions from a low value to a much higher value at a lower moxifloxacin exposure in the continuous-infusion group than in the once-daily administration group. This means that in the continuous-administration mode, the organisms transition into spores earlier, thereby protecting themselves from the hostile environment. Because spores are not metabolically active, they cannot become resistant while in this mode.

FIG. 3.
Relationship between increasing moxifloxacin exposure, as indexed to the AUC (mg·h/liter), when moxifloxacin is administered as a continuous infusion (A) or once daily (B) and the change in the parameter ratio Kvs/Ksv ([filled square]). Both parameters ...

In contrast, the once-daily administration group stays in the vegetative mode longer. This makes them easier to kill but also pushes them into resistance as an alternative survival strategy. The outcome of this can be seen in Fig. Fig.1A1A and and2A2A and Fig. Fig.1C1C and and2C,2C, where failure of therapy due to the emergence of resistance can be seen at 100 mg but not at 150 mg for continuous-infusion administration. Once-daily administration failed due to resistance emergence at 150 mg, but not at 200 mg.

Impact of the administration mode on the emergence of resistance.

Aside from the fact that the organisms stay in the vegetative phase longer, the once-daily mode of administration also has an impact on the emergence of resistance. The integrated impact can be seen most clearly by examining Fig. 4A and B. By simply plotting the number of resistant mutants at the end of the experiment (h 366) as a function of the moxifloxacin AUC (except for the no-treatment control, which shows the number of mutant colonies at baseline), it becomes immediately obvious that the schedule of administration of moxifloxacin had a major impact on the emergence of resistance. The level of drug exposure needed to suppress resistance is slightly more than 50% higher when the drug is administered once daily than when it is administered as a continuous infusion.

FIG. 4.
Approximation of the moxifloxacin AUC (mg·h/liter) that suppresses the amplification of moxifloxacin-resistant subpopulations when the agent is administered as a continuous infusion (A) or once daily (B). For both panels, the number of resistant ...

DISCUSSION

The examination of total populations and total resistant populations (vegetative phase plus spore phase) and of the spore-only populations (total and resistant) demonstrated how complicated the biology of Bacillus anthracis is and how it affects our attempts at chemotherapy.

The behavior of the spore population is particularly intriguing. The control spore population (Fig. (Fig.1B1B and and2B2B controls are the same data) declines continuously after the first 48 h of growth in a nutrient-rich medium. No threat is detected, and the organism stays mostly in vegetative phase (about 10,000-fold more vegetative-phase organisms than spores at day 14). With drug pressure (Fig. 1A and B and 2A and B), if the danger is sensed, the number of spores starts to increase. However, if the pressure is sufficient to suppress or kill the resistant organisms, then the total population and the spore population will fall. It is the ratio of the rate constants governing the transition from the vegetative to the spore phase and from the spore phase back to the vegetative phase (Kvs/Ksv ratio) that determines the final rate of clearance of the total population (determined by extensive simulation from Bayesian estimates). It would appear that there is no sensor for threats for the transition back from the spore phase to the vegetative phase, since this parameter (Ksv) always remains high, irrespective of the exposure or mode of administration. This is in contrast to Kvs, which transitions from a very low value to a much higher value when danger is sensed (probably a quorum-sensing mechanism [5]). Continuously, the spores cycle back to vegetative phase (as determined by Ksv), where they are killed if antibiotic pressure is adequate. If the regimen is not adequate to suppress resistance, then the resistant population will amplify (Fig. (Fig.1C1C and and2C).2C). Interestingly, drug pressure also allows resistant organisms to cycle into the spore population (Fig. (Fig.2D).2D). We believe this to be the first demonstration that resistant organisms can flux into the spore population during therapy. The population of spores increases (see the 100-mg-equivalent regimen in Fig. Fig.1B1B and the 50-, 100-, and 150-mg-equivalent regimens in Fig. Fig.2B,2B, all of which have more spores than the no-treatment control and the successful regimens). This is also evident with the total population (see Fig. Fig.1A1A and and2A2A [100-mg-equivalent continuous-infusion and 50-mg-, 100-mg-, and 150-mg-equivalent once-daily regimens]).

The emergence of resistance, which drives this process, occurs only for the 100-mg-equivalent regimen in the continuous-infusion group but occurs in the 50-mg-, 100-mg-, and 150-mg-equivalent regimens in the daily administration group. Also, resistance emerges after day 3 in the continuous-infusion group but earlier, by 2 days, in the once-daily administration group. Thus, spore formation and the emergence of resistance together influence the outcome of therapy, and the mode of administration alters both spore formation rates and the ease of resistance emergence. The modeling process provides insight here and leads to the question of how to achieve optimal (best cell kill, no resistance emergence) moxifloxacin therapy for Bacillus anthracis.

Optimal chemotherapy can be achieved with moxifloxacin at relatively low exposures. Exposures equivalent to 200 to 250 mg of moxifloxacin per day, administered either once daily or as a continuous infusion with the same daily AUC, produce near-maximal cell kill and suppress the emergence of resistance. For instance, a 200-mg-equivalent exposure to moxifloxacin as a continuous infusion generates a 14-day cell kill of 3.23 log10 CFU/ml, while a 250-mg-equivalent exposure produces a cell kill of 4.02 log10 CFU/ml. These are kills of 0.23 log10 and 0.29 log10 CFU/ml/day, respectively. These exposures as once-daily administration produce kills of 3.49 log10 and 3.98 log10 CFU/ml, with daily kills of 0.25 log10 and 0.28 log10 CFU/ml/day, respectively. With both doses and both administration modes, resistance was suppressed. Consequently, one can say that at relatively low exposures, optimal cell kill and resistance suppression are achievable, irrespective of the mode of administration.

It is important to examine the Bayesian estimates by dose for the rate constants associated with the vegetative-phase-to-spore-phase transition (Kvs) and with the transition back to vegetative phase (Ksv). Kvs is clearly sensitive to drug pressure, indexed to AUC. In Fig. 3A and B, the ratio of Kvs to Ksv is plotted as a function of the moxifloxacin AUC. For the continuous-infusion administration group, the Kvs/Ksv ratio transitions from quite low values to values approximately fivefold higher after a moxifloxacin AUC of approximately 8 mg·h/liter and before an AUC of about 10.6 mg·h/liter. For the once-daily administration group, these values are 13.6 and 15.7 mg·h/liter, indicating that the once-daily administration mode requires a level of drug exposure about 50 to 70% higher than that for continuous infusion to cause the sensing of a threat and faster transition into spore phase. This also implies that the continuous-infusion mode results in more pressure and is more easily sensed. Because of this, the vegetative-phase cells go into spore phase under lower pressure and are able to avoid the threat posed by the drug, while the cells exposed to the once-daily regimen stay in vegetative phase longer and are easier to kill. However, bacteria in the spore phase are metabolically inactive and cannot become resistant (but, as we demonstrated earlier, organisms acquiring resistance in vegetative phase can enter spore phase). The spore-phase organisms eventually reenter vegetative phase and are able to be killed, if the regimen is resistance suppressive.

The two administration modes also have an impact on the emergence of resistance per se. Administration as a continuous infusion shuts off the emergence of resistance in Bacillus anthracis at an AUC0-24 of approximately 9.6 mg·h/liter (Fig. (Fig.4A),4A), while the once-daily mode of administration requires a moxifloxacin AUC0-24 of 14.8 mg·h/liter, a value about 50% greater, to accomplish this (Fig. (Fig.4B).4B). Therefore, the success or failure of a regimen can be said to rely explicitly on drug exposure, but this is modulated through the presence of a spore form, which can shield organisms, as well as by the mode of drug administration, which affects the vegetative/spore transition and the ease with which resistance amplification is suppressed.

In summary, moxifloxacin is able to kill Bacillus anthracis at relatively low dose-equivalent exposures. The success of the regimens is dependent on the mode of administration. Continuous-infusion administration is more easily sensed as a threat by Bacillus anthracis and, at a lower exposure, causes a transition to the spore phase. Continuous-infusion administration also suppresses resistance more efficiently (the time for which the concentration of the drug is above the MIC is the pharmacodynamically linked variable for resistance suppression). The spore phase makes the identification of optimal regimens considerably more complex. Since adherence to a regimen is related to the frequency of administration, moxifloxacin for therapy of Bacillus anthracis should be administered once daily, but at a dose that maximizes the attainment of an AUC/MIC ratio of 253 (AUC, 15.2 mg·h/liter; MIC, 0.06 mg/liter) for wild-type strains (a standard dose of 400 mg produces this MIC 99.7% of the time in a 9,999-subject Monte Carlo simulation).

Further research into the interaction of drug therapy with the quorum-sensing mechanisms in Bacillus anthracis needs to be undertaken (5) in order to ascertain whether this is the mechanism behind the observed change in the transition rate constants.

Acknowledgments

This work was supported by P01AI060908, a grant from NIAID to the Emerging Infections and Pharmacodynamics Laboratory. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

We have no conflicts to disclose.

Footnotes

[down-pointing small open triangle]Published ahead of print on 17 August 2009.

REFERENCES

1. Clinical and Laboratory Standards Institute. 1999. Document M26-A. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2006. Document M7-A7. Methods for dilutional antimicrobial susceptibility testing for bacteria that grow aerobically; approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Deziel, M., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Bassett, L. Miller, K. Bush, M. Kelley, and G. L. Drusano. 2005. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and post-exposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106. [PMC free article] [PubMed]
4. Heine, H. S., A. Louie, F. Sorgel, J. Bassett, L. Miller, L. J. Sullivan, M. Kinzig-Schippers, and G. L. Drusano. 2007. Comparison of two different protein synthesis inhibitor antibiotics for the therapy of Yersinia pestis delivered by aerosol challenge in a mouse model of pneumonic plague. J. Infect. Dis. 196:782-787. [PubMed]
5. Jones, M. B., R. Jani, D. Ren, T. K. Wood, and M. J. Blaser. 2005. Inhibition of Bacillus anthracis growth and virulence-gene expression by inhibitors of quorum sensing. J. Infect. Dis. 191:1881-1888. [PubMed]
6. Leary, R., R. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
7. Louie, A., M. R. Deziel, W. Liu, and G. L. Drusano. 2007. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy. Antimicrob. Agents Chemother. 51:2661-2667. [PMC free article] [PubMed]
8. Louie, A., H. S. Heine, K. Kim, D. L. Brown, B. VanScoy, W. Liu, M. Kinzig-Schippers, F. Sörgel, and G. L. Drusano. 2008. Use of an in vitro model of Bacillus anthracis infection to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance. Antimicrob. Agents Chemother. 52:2486-2496. [PMC free article] [PubMed]
9. Sullivan, J. T., M. Woodruff, J. Lettieri, V. Agarwal, G. J. Kroll, P. T. Leese, S. Watson, and A. H. Heller. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chemother. 43:2793-2797. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)